A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: BL-M02D1
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: SystImmune Inc.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.